- Home
- ATNF vs SNPX Comparison
ATNF vs SNPX Comparison
Compare ATNF & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- SNPX
- Stock Information
- Founded
- ATNF 2016
- SNPX 2012
- Country
- ATNF United States
- SNPX United States
- Employees
- ATNF N/A
- SNPX N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- ATNF Health Care
- SNPX Health Care
- Exchange
- ATNF Nasdaq
- SNPX Nasdaq
- Market Cap
- ATNF 4.1M
- SNPX 3.3M
- IPO Year
- ATNF N/A
- SNPX N/A
- Fundamental
- Price
- ATNF $0.86
- SNPX $2.33
- Analyst Decision
- ATNF
- SNPX Strong Buy
- Analyst Count
- ATNF 0
- SNPX 1
- Target Price
- ATNF N/A
- SNPX $14.00
- AVG Volume (30 Days)
- ATNF 35.6K
- SNPX 7.8K
- Earning Date
- ATNF 05-14-2025
- SNPX 05-14-2025
- Dividend Yield
- ATNF N/A
- SNPX N/A
- EPS Growth
- ATNF N/A
- SNPX N/A
- EPS
- ATNF N/A
- SNPX N/A
- Revenue
- ATNF N/A
- SNPX N/A
- Revenue This Year
- ATNF N/A
- SNPX N/A
- Revenue Next Year
- ATNF N/A
- SNPX N/A
- P/E Ratio
- ATNF N/A
- SNPX N/A
- Revenue Growth
- ATNF N/A
- SNPX N/A
- 52 Week Low
- ATNF $0.90
- SNPX $2.15
- 52 Week High
- ATNF $17.75
- SNPX $6.22
- Technical
- Relative Strength Index (RSI)
- ATNF 36.88
- SNPX 32.87
- Support Level
- ATNF $0.90
- SNPX $2.28
- Resistance Level
- ATNF $1.02
- SNPX $2.78
- Average True Range (ATR)
- ATNF 0.07
- SNPX 0.13
- MACD
- ATNF 0.00
- SNPX -0.03
- Stochastic Oscillator
- ATNF 37.01
- SNPX 28.77
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.